You Are Here: Home > About Arthritis > Arthritis in the News > New Brunswick expands use of biosimilars

New Brunswick expands use of biosimilars

The New Brunswick government is following the lead of other jurisdictions and expanding its use of biosimilar drugs to improve the sustainability of public drug plans, Health Minister Dorothy Shephard announced Wednesday.

Biosimilars are "highly similar," but less expensive versions of originator biologic drugs that are produced once the patent on the first versions expire, according to a news release.

About 3,000 patients with diseases such as arthritis, diabetes, inflammatory bowel disease and psoriasis, who are currently taking originator biologics, have until Nov. 30 to switch to a biosimilar.

Back to News